Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) generates news at the intersection of biotechnology, AI, and cardiovascular medicine. As an artificial intelligence-powered precision cardiovascular medicine company, its announcements often focus on clinical validation of its genetic-epigenetic tests, partnerships with healthcare providers and community organizations, reimbursement milestones, and expansion into new markets.
News coverage for Cardio Diagnostics frequently highlights developments related to its Epi+Gen CHD and PrecisionCHD blood tests for coronary heart disease. Articles include updates on clinical data, such as studies demonstrating PrecisionCHD’s ability to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA), as well as research collaborations that explore inflammation-driven CHD and the use of anti-inflammatory medications alongside molecular testing.
Investors and clinicians following CDIO can also expect news about reimbursement and regulatory progress, including gapfill payment rates from the Centers for Medicare and Medicaid Services and the assignment of CPT Proprietary Laboratory Analysis codes. Additional coverage includes provider network expansion across concierge, functional medicine, and primary care practices in multiple U.S. regions, and community health partnerships with organizations such as YMCA of East Tennessee and Southdale YMCA to bring heart health education and advanced testing to local communities.
International and intellectual property developments are another key news theme. Cardio Diagnostics has reported patents in jurisdictions including Japan, which support its global intellectual property strategy, and has announced its first expansion outside the United States through an agreement to launch the PrecisionCHD test in India with Aimil Ltd. and Dr. Lal PathLabs. For readers interested in how AI, epigenetics, and genetics are being applied to coronary heart disease, the CDIO news stream offers ongoing updates on clinical, commercial, and strategic milestones.
FAQ
What is the current stock price of Cardio Diagnostics Holdings (CDIO)?
What is the market cap of Cardio Diagnostics Holdings (CDIO)?
